RxDoctor Payments DataLook up a doctor →

Ambika Uppu, MD

Family Medicine · Reno, NVNPI 1821285784

Payments from drug & device makers

$10,969in general payments, 2019–2025

Across 644 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • GSK$1K
  • Astellas Pharma US Inc$1K
  • Pfizer$857
  • Novo Nordisk$547
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$10,63197%
  • Education$3383%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,969 in reported general payments places this provider in the 95th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$262,001
Medicare patients
683
Services billed
3,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol93$124,796
OzempicSemaglutide73$119,205
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$57,301
JardianceEmpagliflozin42$53,770
RybelsusSemaglutide21$47,072
EliquisApixaban29$28,797
JanuviaSitagliptin Phosphate23$26,801
NexletolBempedoic Acid23$20,648
Soliqua 100-33Insulin Glargine/Lixisenatide18$20,590
TradjentaLinagliptin13$15,771
Breo ElliptaFluticasone/Vilanterol21$14,760
XareltoRivaroxaban13$10,839
MyrbetriqMirabegron11$9,774
Rosuvastatin Calcium414$8,001
Levothyroxine Sodium480$6,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$547$166,27794 claims
AstraZenecaFarxiga, Symbicort$1,182$130,250109 claims
GSKTrelegy Ellipta, Breo Ellipta$1,082$72,06176 claims
Boehringer IngelheimJardiance, Tradjenta$476$69,54155 claims
PfizerEliquis$857$28,79729 claims
MerckJanuvia$381$26,80123 claims
Esperion Therapeutics, Inc.Nexletol$195$20,64823 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$140$20,59018 claims
Johnson & JohnsonXarelto$139$10,83913 claims
Astellas Pharma US IncMyrbetriq$1,026$9,77411 claims
AbbVieSynthroid$1,195$4,90961 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 902 family medicine providers in Nevada.

Other family medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →